Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

OmSanA: A natural dietary supplement for maintaining blood sugar and cholesterol levels

As the nation prepares to watch the ball drop in Times Square, Americans will reminisce about the past year and make resolutions for 2010—many will be focused on getting and remaining healthy—and just being normal. Yes, that’s right…normal.

31 Dec 2009

Relieve stress: Exercise, meditate, delegate tasks, diet and be happy

It's impossible to know, unless you're Urban Meyer or one of his doctors, what exactly caused the two-time college football championship winner to see-saw decisions about his prestigious professional career and his family life.

30 Dec 2009

Overview of Psoriasis

Psoriasis, a chronic disease that causes red, raised patches of skin, is increasingly seen as a systemic disease with links to arthritis and cardiovascular disease. The December issue of Mayo Clinic Women's HealthSource provides an overview of this sometimes embarrassing condition, what's known about it and how it's treated.

30 Dec 2009

ACC files complaint against HHS Secretary in U.S. District Court

The American College of Cardiology (ACC) today announced that it filed a complaint against the Department of Health and Human Services (HHS) Secretary Kathleen Sebelius in United States District Court.

30 Dec 2009

VIA Pharmaceuticals receives NASDAQ delisting notice

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.

29 Dec 2009

Study suggests genetic variations predispose African-Americans to diabetes

For years, scientists have tried to determine the basis for discrepancies between race and the predisposition for development of diseases such as type II diabetes and cardiovascular disease. Could factors such as differences in lifestyle or access to health care play a role, or is there something else in play?

29 Dec 2009

Childhood ETS may lead to emphysema

Children regularly exposed to tobacco smoke at home were more likely to develop early emphysema in adulthood. This finding by researchers at Columbia University's Mailman School of Public Health suggests that the lungs may not recover completely from the effects of early-life exposures to tobacco smoke (ETS). The study is published in the December 2009 American Journal of Epidemiology.

29 Dec 2009

Union Bank and AHA announce new sponsorship agreement

Union Bank, N.A., and The American Heart Association (AHA) have announced a four-year agreement to promote the AHA’s Start! movement in Los Angeles, Orange, and San Diego counties.

24 Dec 2009

ABBM grants certification for medical community who treats obesity and related conditions

The American Board of Bariatric Medicine (ABBM) recently administered its certification exam designed to recognize doctors, nurse practitioners and physicians assistants who practice bariatric medicine and the non-surgical medical management of overweight and obese patients.

23 Dec 2009

ARCA biopharma submits Gencaro trial protocol for review under the FDA’s SPA process

ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.

23 Dec 2009

Cardiac rehabilitation improves survival rate in heart attack patients

Medicare beneficiaries with heart disease who attended more cardiac rehabilitation sessions had fewer heart attacks and were less likely to die within four years than those who went to rehab less, researchers report in Circulation: Journal of the American Heart Association.

23 Dec 2009

LA BioMed physician-researchers named Super Doctors in the Los Angeles Magazine

Los Angeles Magazine, in its January issue, will name 37 of the physician-researchers at Los Angeles Biomedical Research Institute (LA BioMed) to be among Southern California Super Doctors.

22 Dec 2009

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

Access to convenience stores can pormote childhood obesity

Childhood obesity is directly related to how close kids live to convenience stores, according to the preliminary findings of a major Canadian study presented at the Entretiens Jacques-Cartier in Lyon, France. The ongoing study is named QUALITY for Quebec Adipose and Lifestyle InvesTigation in Youth.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Shift working may accelerate metabolic syndrome

Shift work exposures can accelerate metabolic syndrome (MetS) development among the large population of middle-aged males with elevated alanine aminotransferase (ALT). Elevated serum alanine aminotransferase (e-ALT) is a common abnormality of health examinations in middle-aged working populations.

17 Dec 2009

New Tandem fund of $300 million presents financing option for Canada’s biotechnology industry

The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada’s biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.

17 Dec 2009

ESC CV Imaging textbook for trainees and cardiologists

Imaging is at the heart of diagnostic procedures in cardiology. The idea of publishing an ESC Textbook of Cardiovascular Imaging which accumulates the expertise of European cardiovascular imagers, is therefore long awaited.

17 Dec 2009